Toll-like receptor-4 expression by stromal fibroblasts is associated with poor prognosis in colorectal cancer

Journal of Immunotherapy

Volumn 36, Issue 6, 2013, Pages 342-349

  Eiró, Noemí ^a   González, Lucía ^a   González, Luis O ^a   Fernandez Garcia, Belen ^a   Andicoechea, Alejandro ^a   Barbón, Esther ^a   García Muñiz, José L ^a   Vizoso, Francisco J ^a  

^a HOSPITAL DE JOVE   (Spain)

Author keywords

Colorectal cancer; Fibroblasts; Prognosis; TLR4

Indexed keywords

TOLL LIKE RECEPTOR 4; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CANCER RECURRENCE; CELL TYPE; COLORECTAL CANCER; FEMALE; FIBROBLAST; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM; RECTUM TUMOR;

ADULT; AGED; COLORECTAL NEOPLASMS; FEMALE; FIBROBLASTS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; STROMAL CELLS; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTORS;

EID: 84880206477     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31829d85e6     Document Type: Article

References (58)

1. Tenesa A, Dunlop MG. New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat Rev Genet. 2009;10:353-358.
2. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
3. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6:392-401.
4. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004;432:332-337.
5. Silzle T, Randolph GJ, Kreutz M, et al. The fibroblast: sentinel cell and local immune modulator in tumor tissue. Int J Cancer. 2004;108:173-180.
6. Ingerslev HC, Ossum CG, Lindenstrom T, et al. Fibroblasts express immune relevant genes and are important sentinel cells during tissue damage in rainbow trout (Oncorhynchus mykiss). PLoS One. 2010;5:e9304.
7. Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer. 2009;9:57-63.
8. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454:436-444.
9. Killeen SD, Wang JH, Andrews EJ, et al. Exploitation of the toll-like receptor system in cancer: a doubled-edged sword? Br J Cancer. 2006;95:247-252.
10. Fukata M, Chen A, Vamadevan AS, et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology. 2007;133:1869-1881.
11. He W, Liu Q, Wang L, et al. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol. 2007;44:2850-2859.
12. Gonzalez-Reyes S, Fernandez JM, Gonzalez LO, et al. Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence. Cancer Immunol Immunother. 2011;60:217-226.
13. Gonzalez-Reyes S, Marin L, Gonzalez L, et al. Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer. 2010;10:665-673.
14. Eiro N, Ovies C, Fernandez-Garcia B, et al. Expression of TLR3, 4, 7 and 9 in cutaneous malignant melanoma: relationship with clinicopathological characteristics and prognosis. Arch Dermatol Res. 2013;305:59-67.
15. Castro FA, Forsti A, Buch S, et al. TLR-3 polymorphism is an independent prognostic marker for stage II colorectal cancer. Eur J Cancer. 2011;47:1203-1210.
16. O'Leary DP, Bhatt L, Woolley JF, et al. TLR-4 signalling accelerates colon cancer cell adhesion via NF-kappaB mediated transcriptional up-regulation of Nox-1. PLoS One. 2012;7:e44176.
17. Grimm M, Kim M, Rosenwald A, et al. Toll-like receptor (TLR) 7 and TLR8 expression on CD133+ cells in colorectal cancer points to a specific role for inflammation-induced TLRs in tumourigenesis and tumour progression. Eur J Cancer. 2010;46:2849-2857.
18. Rayburn ER, Wang W, Zhang R, et al. Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53. Int J Oncol. 2007;30:1511-1519.
19. Hermaneck P. S.L. TNM Classification of Malignant Tumors. 6th ed. Berlin: Springer; 2002.
20. Dukes C. The classification of cancer of the rectum. J Pathol Bacteriol. 1932;35:323-332.
21. Vizoso FJ, Gonzalez LO, Corte MD, et al. Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer. 2007;96:903-911.
22. Eiro N, Gonzalez LO, Atienza S, et al. Prediction of metastatic breast cancer in non-sentinel lymph nodes based on metalloprotease-1 expression by the sentinel lymph node. Eur J Cancer. 2013;49:1009-1017.
23. Rakoff-Nahoum S, Medzhitov R. Role of toll-like receptors in tissue repair and tumorigenesis. Biochemistry (Mosc). 2008;73: 555-561.
24. Kelly MG, Alvero AB, Chen R, et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 2006;66:3859-3868.
25. Naugler WE, Sakurai T, Kim S, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 2007;317:121-124.
26. Schwartz AL, Malgor R, Dickerson E, et al. Phenylmethimazole decreases toll-like receptor 3 and noncanonical Wnt5a expression in pancreatic cancer and melanoma together with tumor cell growth and migration. Clin Cancer Res. 2009;15: 4114-4122.
27. Kawai T, Akira. S. TLR signaling. Cell Death Differ. 2006;13:816-825.
28. Eiro N, Gonzalez L, Gonzalez LO, et al. Study of the expression of toll-like receptors in different histological types of colorectal polyps and their relationship with colorectal cancer. J Clin Immunol. 2012;32:848-854.
29. Huang B, Zhao J, Li H, et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. 2005;65:5009-5014.
30. Huang B, Zhao J, Unkeless JC, et al. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene. 2008;27: 218-224.
31. Nunez NG, Andreani V, Crespo MI, et al. IFNbeta produced by TLR4-activated tumor cells is involved in improving the antitumoral immune response. Cancer Res. 2012;72:592-603.
32. Wang EL, Qian ZR, Nakasono M, et al. High expression of toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. Br J Cancer. 2010;102:908-915.
33. Nihon-Yanagi Y, Terai K, Murano T, et al. Tissue expression of Toll-like receptors 2 and 4 in sporadic human colorectal cancer. Cancer Immunol Immunother. 2012;61:71-77.
34. Hoffmann A, Baltimore D. Circuitry of nuclear factor kappaB signaling. Immunol Rev. 2006;210:171-186.
35. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27:5904-5912.
36. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21:309-322.
37. Gonzalez LO, Gonzalez-Reyes S, Marin L, et al. Comparative analysis and clinical value of the expression of metalloproteases and their inhibitors by intratumour stromal mononuclear inflammatory cells and those at the invasive front of breast carcinomas. Histopathology. 2010;57:862-876.
38. Gonzalez LO, Pidal I, Junquera S, et al. Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasisrelapse. Br J Cancer. 2007;97:957-963.
39. Del Casar JM, Gonzalez LO, Alvarez E, et al. Comparative analysis and clinical value of the expression of metalloproteases and their inhibitors by intratumor stromal fibroblasts and those at the invasive front of breast carcinomas. Breast Cancer Res Treat. 2009;116:39-52.
40. Gonzalez LO, Gonzalez-Reyes S, Junquera S, et al. Expression of metalloproteases and their inhibitors by tumor and stromal cells in ductal carcinoma in situ of the breast and their relationship with microinvasive events. J Cancer Res Clin Oncol. 2010;136:1313-1321.
41. Fernandez-Gomez J, Escaf S, Gonzalez LO, et al. Relationship between metalloprotease expression in tumour and stromal cells and aggressive behaviour in prostate carcinoma: simultaneous high-throughput study of multiple metalloproteases and their inhibitors using tissue array analysis of radical prostatectomy samples. Scand J Urol Nephrol. 2011;45:171-176.
42. Escaff S, Fernandez JM, Gonzalez LO, et al. Collagenase-3 expression by tumor cells and gelatinase B expression by stromal fibroblast-like cells are associated with biochemical recurrence after radical prostatectomy in patients with prostate cancer. World J Urol. 2011;29:657-663.
43. Koch M, Beckhove P, Op den Winkel J, et al. Tumor infiltrating T lymphocytes in colorectal cancer: tumor-selective activation and cytotoxic activity in situ. Ann Surg. 2006;244:986-992; discussion 992-3.
44. Deschoolmeester V, Baay M, Van Marck E, et al. Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. BMC Immunol. 2010;11:19-30.
45. Tougeron D, Fauquembergue E, Rouquette A, et al. Tumorinfiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutations. Mod Pathol. 2009;22: 1186-1195.
46. Jedinak A, Dudhgaonkar S, Sliva D. Activated macrophages induce metastatic behavior of colon cancer cells. Immunobiology. 2010;215:242-249.
47. Goke M, Kanai M, Podolsky DK. Intestinal fibroblasts regulate intestinal epithelial cell proliferation via hepatocyte growth factor. Am J Physiol. 1998;274:G809-G818.
48. Kessler S, Seiki S, Sinha. N. Xcl1 causes delayed oblique periclinical cell divisions in developing maize leaves, leading to cellular differentiation by lineage instead of position. Development. 2002;129:1859-1869.
49. Tsujino T, Seshimo I, Yamamoto H, et al. Stromal myofibroblasts predict disease recurrence for colorectal cancer. Clin Cancer Res. 2007;13:2082-2090.
50. Guo X, Oshima H, Kitmura T, et al. Stromal fibroblasts activated by tumor cells promote angiogenesis in mouse gastric cancer. J Biol Chem. 2008;283:19864-19871.
51. Sheyhidin I, Nabi G, Hasim A, et al. Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma. World J Gastroenterol. 2011;17:3745-3751.
52. Hartman ZC, Osada T, Glass O, et al. Ligand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunity. Cancer Res. 2010;70:7209-7220.
53. Cammarota R, Bertolini V, Pennesi G, et al. The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker. J Transl Med. 2010;8:112-127.
54. Gonzalez L, Eiro N, Gonzalez LO, et al. Effect of the expression of matrix metalloproteases and their tissue inhibitors on survival of patients with resectable colorectal cancer. Dig Dis Sci. 2012;57:2063-2071.
55. Merrell MA, Ilvesaro JM, Lehtonen N, et al. Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res. 2006;4:437-447.
56. Lee Y, Kim H, Kim S, et al. Activation of toll-like receptors 2, 3 or 5 induces matrix metalloproteinase-1 and -9 expression with the involvement of MAPKs and NF-kappaB in human epidermal keratinocytes. Exp Dermatol. 2010;19:e44-e49.
57. Agarwal S, Misra R, Aggarwal A. Induction of metalloproteinases expression by TLR ligands in human fibroblast like synoviocytes from juvenile idiopathic arthritis patients. Indian J Med Res. 2010;131:771-779.
58. Rath T, Stockle J, Roderfeld M, et al. Matrix metalloproteinase-13 is regulated by toll-like receptor-9 in colorectal cancer cells and mediates cellular migration. Oncol Lett. 2011;2: 483-488.